Here, we present an alternative therapeutic strategy for MuSK MG, by targeting the trophic MuSK pathway directly with a MuSK agonist antibody, thus counteracting the inhibitory effect of the patients' pathogenic MuSK autoantibodies. Here, MUSK is linked to myasthenia gravis.